Design and evaluation of novel inhibitors for the treatment of clear cell renal cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Design and evaluation of novel inhibitors for the treatment of clear cell renal cell carcinoma

Published:2024-10 Issue: Volume:151 Page:107597
ISSN:0045-2068
Container-title:Bioorganic Chemistry
language:en
Short-container-title:Bioorganic Chemistry

Author:

Bouzian Younos,El Hafi Mohamed,Parvizi Negar,Kim Woonghee,Subaşioğlu Mine^ORCID,Ozcan Mehmet,Turkez Hasan,Mardinoglu Adil

Publisher

Elsevier BV

Reference33 articles.

1. NCCN guidelines insights: kidney cancer, version 1.2021: featured updates to the NCCN guidelines;Motzer;J. Natl. Compr. Canc. Netw.,2020

2. Mechanisms of acquired resistance to tyrosine kinase inhibitors in clear-cell renal cell carcinoma (ccRCC);Bielecka;Curr. Signal Transduct. Ther.,2013

3. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma;Méndez-Vidal;BMC Pharmacol. Toxicol.,2018

4. Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: a narrative review;Liu;Int. Immunopharmacol.,2022

5. M. p. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N. Engl. J. Med.,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP